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One of the most popular nicotine replacement therapies (NRTs)
available in the market nowadays is the nicotine patches, which
provide a source of nicotine to reduce the withdrawal symp-
toms experienced when smoking is stopped. Nicotine
transdermal patch to satisfy addicted smoker’s cravings as on-
invasive, self medicated therefore patient compliance and less
frequent administration than oral was investigated to contain
2 layers; backing layer, adhesive with drug layer. Several poly-
mers such as hydroxypropyl methylcellulose (HPMC) E5,
PEG4000, PVP K30, Eudragit E100, maltodextrin, polyvinyl alcohol
(PVA), xanthan gum and carbopol were used as film formers;
polyethylene glycol (PEG) 400, triacetin, propylene glycol and
glycerin were used as plasticizers. Polymers and plasticizers
were able to form homogeneous mixture, and the patches were
easily prepared by pouring them into plates followed by drying
them in a hot air oven at 50 °C for 4 hours. Finally, the patches
were evaluated to study the effect of type and content of poly-
mers and plasticizers that were suitable for transdermal patch
such as thickness, tensile strength, Young’s modulus, inter-
nal structure, drug release and drug content following USP
monograph.
Eudragit E100 with HPMC E5, PEG4000, and PVP K30 pro-
duced satisfactorily clear and elastic films (Fig. 1a) with
satisfactory mechanical properties, determined from a uni-
versal tensile tester. HPMC E5, PEG4000 and PVP K30 could form
pores due to their water solubility, thus increased drug release.
When using PVA, maltodextrin, xanthan gum and carbopol,
unclear film was obtained. For PEG400, triacetin and propyl-
ene glycol as plasticizer, glycerin was not suitable because film
characteristic was too sticky. The amount of Eudragit E100 sig-
nificantly affected the drug release, while slight alteration in
drug release was observed from other polymers (Fig. 1b). The
results indicated that the polymeric patches composed of these
polymers were suitable for developing nicotine transdermal
patches with the composition of 4%, 1.4%, 0.5% and 0.8% of
Eudragit E100, HPMC E5, PEG4000 and PVP K30, respectively.
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Fig. 1 – Skin adhesion of selected patch (a) and drug release profile (b): Eudragit E100 4% (Formula A), Eudragit E100 10%
(Formula B), Eudragit L100 4% (Formula C), Eudragit L100 4% (Formula D).
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